Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gold-198 nanoparticle depot (also known as [198Au]AuNPD) is a preclinical-stage intratumorally administered radiation nanomedicine being developed by researchers at the University of Toronto, McMaster University, and the University Health Network. It consists of gold-198 (198Au)-labeled gold nanoparticles packaged into a biodegradable calcium alginate seed (nanodepot). Gold-198 is a beta-particle emitter (t1/2 = 2.7 days, Eβmax = 0.96 MeV) that delivers a high, localized, and conformal radiation dose to the tumor tissue, minimizing exposure to surrounding healthy organs. The nanodepot is designed for local brachytherapy-like insertion. In preclinical models of triple-negative breast cancer (TNBC), the gold-198 nanoparticle depot has been evaluated alone and in combination with chemotherapeutic agents like doxorubicin or immune checkpoint inhibitors like atezolizumab, demonstrating significant inhibition of primary tumor growth and improvement in median survival.
| Indication | Highest phase | Status |
|---|---|---|
| triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gold-198 nanoparticle depot.
Work on gold-198 nanoparticle depot? Claim this page to correct or add information. Claim this page